- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04355572
Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients referred to the pediatric endocrinology clinic or adolescent gynecology clinic at Yale New Haven Children Hospital with a primary complaint of hirsutism, acne, or amenorrhea and/or oligomenorrhea persisting 2 years after their menarche will be evaluated for polycystic ovarian syndrome through history, physical exam, pelvic ultrasound, and laboratory evaluation, to include androgen testing, thyroid testing, female hormone testing, and diabetic risk testing (this is standard of care). A vitamin D level will also be drawn. While vitamin D level is not currently part of the diagnostic algorithm for PCOS, it is not unreasonable to check in patients in which there is concern for an endocrine disorder. If the patient meets Rotterdam criteria and their serum vitamin D level is between 6 and 29 ng/mL, the patient and their guardian(s) will be approached for inclusion in our study by the physician or dedicated research nursing staff.
If patient and guardian agree to participate and sign a consent / assent form, the patient will then be randomized to receive vitamin D supplement versus placebo and will be followed for 6 months on their randomized replacement with repeat laboratory testing of AMH, vitamin D, lipid profile, glucose and insulin testing, androgen testing, and female hormone testing at the randomization, 3 months and at the end of the course of the trial(6 months). Patients with vitamin D levels 5ng/mL or less will not be randomized, they will be given recommended treatment. Depressive symptoms will be assessed at time of randomization, 3 months post randomization, and 6 months post randomization using the Beck Depression Inventory-II, the gold standard self-report depression inventory. A depression screen is currently administered to all adolescents seen at Yale New Haven Children Hospital outpatient clinics with a protocol for patients who report clinically significant levels of depression. This protocol will remain in place and will not be altered during this research study.
After post-trial testing, patients will be unblinded and patients who still have vitamin D below threshold will be offered vitamin D treatment.
Aim 1: To investigate the effect of vitamin D replacement upon biochemical parameters of polycystic ovarian syndrome (PCOS) in adolescent female patients. Hypothesis: Replacement of vitamin D to normal levels in adolescents with PCOS and/or at risk for PCOS and low levels of vitamin D will lower serum androgen and anti-mullerian hormone (AMH) levels.
Aim 2: To investigate the effect of vitamin D replacement on clinical features of PCOS in adolescent female patients. Hypothesis: Replacement of vitamin D in adolescents with PCOS and/or at risk for PCOS and low levels of vitamin D will improve symptoms of menstrual irregularities, acne, and hirsutism.
Aim3: To investigate the effect of vitamin D replacement on depressive symptoms in adolescent female patients with PCOS. Hypothesis: Replacement of vitamin D in adolescents with PCOS or at risk for PCOS and low levels of serum vitamin D will improve symptoms of depression.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alla Vash-Margita, MD
- Phone Number: 203-785-4010
- Email: alla.vash-margita@yale.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Postmenarchal adolescent females aged 13-21 who meet modified Rotterdam criteria for PCOS, with a serum vitamin D level between 6-29 ng/mL.
Exclusion Criteria:
- Other causes for hyperandrogenism,
- Chronic renal diseases,
- Acquired or inherited calcium and vitamin D metabolic disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin D Supplement
Patients will take vitamin D tablet with 4,000IU daily for 6 months.
|
Randomized to receive vitamin D 4000IU daily
|
Placebo Comparator: Placebo
Patients will take placebo for 6 months
|
Randomized to placebo daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oligomenorrhea
Time Frame: 6 months
|
The change in oligomenorrhea, i.e restoration of monthly menses or improvement in the menstrual pattern during 6 months while enrolled in the trial based on self report
|
6 months
|
Changes Vitamin D (25-hydroxyvitamin D) level
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
25-hydroxyvitamin D level will be measured by liquid chromatography-mass spectrometry (LC-MS/MS) or immunoassay
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in DHEAS level
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
The serum DHEA-S concentration is the traditional marker for adrenal androgen excession because it is produced almost exclusively by the adrenal glands and concentrations remain stable across the day and cycle.
Preferred testing is done by immunoassay.
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Changes in Androstenedione level
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
Androstenedione concentration assesses for hyperandrogenemia as well, it is produced by the ovary and the adrenal cortex and serves as precursor of testosterone.
Data suggests that levels are elevated in approximately 20% of women with PCOS.
Evaluation is done by Liquid Chromatography/Tandem Mass Spectrometry
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Change in Anti-Mullerian hormone (AMH) level
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
AMH is a dimeric glycoprotein of the transforming growth factor-β superfamily that is involved in growth and differentiation of ovarian follicles.
AMH is expressed in granulosa cells in the ovary and serves as a marker of ovarian reserve as well as marker of several ovarian pathologies such as PCOS, granulosa cell tumors and premature ovarian insufficiency.
Level will be measured using Immunoassay (IA)
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Change in testosterone level
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
Testosterone levels are elevated in vast majority of adolescents with PCOS.
The free testosterone level is more sensitive for diagnosis of hyperandrogenic disorders compared with the total testosterone.
Evaluation is done by Chromatography/Mass Spectrometry
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Change in Hirsutism
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
Hirsutism is defined as excessive male-pattern facial and body hair.
This will be measured by using the modified Ferriman Gallwey score by a provider with scores of less than 6 indicating no evidence of hirsutism, 6-8 indicating mild hirsutism, scores 8-15 indicating moderate hirsutism and scores greater than 15 indicating severe hirsutism.
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Change Body Acne
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
European Dermatology Forum Guidelines group (2011) grading system will be used to describe acne in 4 areas of the body- face, upper chest, upper back, upper arms: minimal - comedonal acne, mild to moderate: moderate papulopustular acne, severe: severe papulopustular acne, moderate nodular acne; severe nodular acne,conglobate acne
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Change in Facial
Time Frame: at enrollment, at 3 months after randomization and 6 months after randomization
|
European Dermatology Forum Guidelines group (2011) grading system will be used to describe acne in 4 areas of the body- face, upper chest, upper back, upper arms: minimal - comedonal acne, mild to moderate: moderate papulopustular acne, severe: severe papulopustular acne, moderate nodular acne; severe nodular acne,conglobate acne
|
at enrollment, at 3 months after randomization and 6 months after randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alla Vash-Margita, MD, Yale University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Endocrine System Diseases
- Disease
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Nutrition Disorders
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Polycystic Ovary Syndrome
- Syndrome
- Vitamin D Deficiency
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Vitamin D
Other Study ID Numbers
- 2000028054
- 000 (Other Identifier: CTGTY)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
Clinical Trials on Vitamin D 4000IU daily
-
University of LeedsNot yet recruitingChronic Heart FailureUnited Kingdom
-
Murdoch Childrens Research InstituteSuspended
-
Tartu University HospitalUniversity of Tartu; Estonian Defence ForcesCompletedVitamin D Deficiency | Physical Stress | Military ActivityEstonia
-
University of ViennaUnknown
-
University College DublinUniversity of UlsterCompleted
-
University of PittsburghNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedOsteoporosis | Bone Loss | Fragility FracturesUnited States
-
Medical University of South CarolinaGrassroots Health Nutrition Institute; ZRT LaboratoryActive, not recruitingCOVID-19 | Vitamin D Deficiency | Respiratory Viral InfectionUnited States
-
King Faisal Specialist Hospital & Research CenterWithdrawnVitamin D DeficiencySaudi Arabia
-
St. Justine's HospitalCompletedCrohn's DiseaseCanada
-
University of HelsinkiPäivikki and Sakari Sohlberg Foundation, Finland; Lilly FoundationCompleted